

# **Clinical Trial Supplies**

## **Contents**

### **Chapter 1**

#### **Clinical Trial Supplies – The Essential Ingredients**

**By Dr Patricia Lobo, Technomark Consulting Services**

1. Introduction
2. CTS, a Definition
3. Outsourcing
4. Clinical Trials Supplies, Activities
  - 4.1 Manufacturing
  - 4.2 Packing
  - 4.3 Labelling
  - 4.4 Storage, Warehousing and Distribution
  - 4.5 Reconciliation and Destruction of CTS
  - 4.6 Process Improvement
  - 4.7 Quality
5. The Market for CTS
  - 5.1 CTSO, a Definition
  - 5.2 Location
  - 5.3 Classification of CTSOs
  - 5.4 Growing the CTS Business
  - 5.5 Annual Revenue of CTSOs
  - 5.6 Number of Employees of CTSOs
  - 5.7 CTSO Facilities and Global Scope
  - 5.8 Clinical Trial Supply Services
6. Client Survey
  - 6.1 Why Outsource Clinical Trial Supplies
  - 6.2 Criteria for Choosing a CTSO
  - 6.3 CTS Services Availability
7. Forecasting CTS Business – the Challenge

## **Chapter 2**

### **Development, Formulation and Manufacture of Investigational Medicinal Products**

**By John DR Jolly, FRPharmS, FIQA**

1. Introduction
2. Drug Discovery
  - 2.1 Stages in the Development of New Medicines
  - 2.2 Chemical, Pharmaceutical and Biological Screening
  - 2.3 Pre-clinical Toxicological Testing
3. Formulation of Dose Form
  - 3.1 Pre-formulation
  - 3.2 Modified Release Dosage Forms
  - 3.3 Drug Pharmacokinetics
  - 3.4 Product Specification
  - 3.5 Stability Testing
4. Manufacture of Investigational Medicinal Product
  - 4.1 Regulatory Framework
  - 4.2 Quality Characteristics
  - 4.3 Good Manufacturing Practice

## **Chapter 3**

### **The Role of Analytical Development in CTS**

**By Geoff Carr PhD, Patheon Inc**

1. Introduction
2. Regulatory Considerations
3. Development of Appropriate Analytical Methodologies
  - 3.1 Analytical Methods for Phase I Clinical Trial Materials
  - 3.2 Analytical Methods for Phase II and III Clinical Trial Materials
    - 3.2.1 Excipient Compatibility Studies
    - 3.2.2 High Performance Liquid Chromatography
    - 3.2.3 Pharmaceutical Performance
    - 3.2.4 Feasibility Batches
    - 3.2.5 Verification of Cleaning Methods
4. Validation of Analytical Methodologies

5. Stability Programs
6. Placebo Formulations
7. Blinded Clinical Comparators

## **Chapter 4 Packaging Types**

**By Nicola Mountjoy, Aptuit**

1. Introduction
2. Technical
  - 2.1 Primary Packaging
    - 2.1.1 Blistering/Foils
    - 2.1.2 Bottling
    - 2.1.3 Child Resistant Packaging
  - 2.2 Secondary Packaging
    - 2.2.1 Blinding
    - 2.2.2 Assembly
  - 2.3 Labelling
    - 2.3.1 Application
    - 2.3.2 Standard/Booklets/JIT
    - 2.3.3 Labelling at Controlled temperature
3. Summary

## **Chapter 5 CTS – The Regulatory Challenge**

**By Keren Winmill, Penn Pharmaceutical Services**

1. Introduction
2. History
3. The Regulatory Framework in Europe
4. Interpretation of European Requirements

- 4.1 Clinical Trial Applications/Ethics
- 4.2 The Role of the Qualified Person
- 4.3 Manufacturing Authorisation
- 4.4 Product Specification File
- 4.5 Label Requirements
- 4.6 Expiry Dating
- 4.7 Importation into Europe
- 4.8 GMP
- 4.9 Inspections
  
- 5. United States
  - 5.1 Regulations and Guidances
  - 5.2 Label Requirements
  - 5.3 Child Resistant Packaging
  
- 6. Active Pharmaceutical Ingredient
  
- 7. Compassionate Use and Named Patient Supply
  
- 8. Drug Device Combinations
  
- 9. Conclusions

## **Chapter 6**

### **Automated Logistics and Distribution**

**By Anthony Frankland, Fisher Clinical Services**

- 1. Introduction
  
- 2. The Clinical Trials Environment and Implications for Clinical Supplies
  - 2.1 Major Pharmaceutical Companies
  - 2.2 Biotechnology
  - 2.3 Commercialisation of Biopharm Products
  - 2.4 European Union Expansion
  - 2.5 IVR Driven Studies
  - 2.6 Consolidation of Clinical Supplies
  - 2.7 Summary of Implications
  
- 3. The Application of Technology and Automation in Clinical Distribution
  - 3.1 Receipt and Processing of Distribution Orders
  - 3.2 Picking and Packing of Orders
  - 3.3 Couriers and Web Technology
  
- 4. The Use of Information Technology to Optimise the Supply Plan

5. The Extension of IVR Technology
6. Trial Simulation and Forecasting

## **Chapter 7**

### **Supplying the Needs of Emerging Markets**

**By Richard Shannon, Clinical Trial Services - Almac**

1. Introduction
2. Why Perform Clinical Trials in Emerging Markets
3. Which Regions are Considered Emerging Markets?
  - 3.1 Asia
  - 3.2 India
  - 3.3 Central and Eastern Europe
  - 3.4 Latin America
  - 3.5 Africa
4. Logistical Challenges
5. Selection of Market Partners
6. Obtaining Import Licences
7. Use of Strategic Distribution Depots
  - 7.1 Direct to Site Distribution
  - 7.2 Distribution to Local Depots
  - 7.3 Hybrid Approaches
8. Cold Chain Management
  - 8.1 Packaging for Maintenance of Temperature Control
  - 8.2 Use of Monitoring Devices
  - 8.3 Transit Times
  - 8.4 Planning for Deviations
9. Conclusion

## **Chapter 8**

### **A Note on Scheduling, Planning and Project Management**

**By Alistair Black, Aptuit**

1. Planning for CTS
2. The Phases of a Project
  - 2.1 Initiation
  - 2.2 Specification
  - 2.3 Design
  - 2.4 Implementation/Operations
3. Risk Analysis
  - 3.1 Identify the Risks
4. Milestones
5. Controlling Projects
  - 5.1 Taking action